EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching

Shin-Ichiro Ohmura iD

Modern Rheumatology · 04.11.2026 · 36 (6) · 869-875

DOI: 10.1093/mr/roag070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Modern Rheumatology, online erschienen am 19.08.2026. Verfasst von Shin-Ichiro Ohmura. Beteiligte Einrichtung: Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methotrexate (MTX) remains the anchor drug in the management of rheumatoid arthritis. However, its clinical use is frequently limited by intolerance, leading to dose reduction or discontinuation. In addition, oral MTX exhibits pharmacokinetic limitations, including dose-dependent absorption and reduced bioavailability at higher doses, which may compromise therapeutic efficacy. Subcutaneous (SC) MTX has emerged as a strategy to overcome these limitations by providing more consistent bioavailability and potentially improved tolerability. Evidence suggests that switching from oral-to-SC MTX may improve gastrointestinal intolerance and support treatment persistence, whereas evidence for improved disease control or reduction of serious MTX-related toxicity remains limited. Recent Japanese studies suggest the potential utility of this approach at MTX doses commonly used in Japan, although evidence for the superiority of SC MTX over oral MTX in low-dose settings remains limited. This narrative review summarizes current evidence on MTX intolerance and oral-to-SC route switching in rheumatoid arthritis, with a focus on practical strategies for treatment optimization. Overall, oral-to-SC MTX switching may represent an important option to improve gastrointestinal intolerance and support treatment persistence in patients with rheumatoid arthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateArthritis, RheumatoidAntirheumatic AgentsHumansAdministration, OralInjections, Subcutaneous

Stichwörter der Autor:innen

intolerancemethotrexaterheumatoid arthritissubcutaneousswitching

Substanzen

MethotrexateAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.

ORCID-Profile: Shin-Ichiro Ohmura

Zitieren

APA

Ohmura, S. I. (2026). Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching. Modern Rheumatology, 36(6), 869-875. https://doi.org/10.1093/mr/roag070

Vancouver

Ohmura SI. Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching. Modern Rheumatology. 2026;36(6):869-875. doi:10.1093/mr/roag070

BibTeX
@article{Ohmura2026,
  author = {Ohmura, Shin-Ichiro},
  title = {Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching},
  journal = {Modern Rheumatology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {869--875},
  doi = {10.1093/mr/roag070}
}
Kostenlos starten →